Expression of MUC1 (Ma695) in noninvasive papillary urothelial neoplasm according to the 2004 world health organization classification of the noninvasive urothelial neoplasm: An immunologic tool for the pathologist?

Analytical and Quantitative Cytology and Histology

Volumn 33, Issue 5, 2011, Pages 277-282

  Garbar, Christian ^a   Mascaux, Corinne ^a  

^a INSTITUT JEAN GODINOT   (France)

Author keywords

Bladder carcinoma; MUC1

Indexed keywords

MUCIN 1;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BLADDER TUMOR; CANCER GRADING; CONTROLLED STUDY; CYTOPLASM; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NONINVASIVE PAPILLARY UROTHELIAL NEOPLASM; PATHOLOGIST; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA, PAPILLARY; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUCIN-1; PATHOLOGY, CLINICAL; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 84861164855     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Dall'olio F: Protein glycosylation in cancer biology: An overview. Clin Mol Pathol 1996;49:M126-M135.
2. Springer GF, Heather M: T and Tn pancarcinoma markers: Autoantigenic adhesion molecules in pathogenesis, prebiopsy carcinoma-detection, and long-term breast carcinoma immunotherapy. Crit Rev Oncol 1995;6:57-85.
3. Limacher JM, Acres B: MUC1, a therapeutic target in oncology. Bull Cancer 2007;94:253-257.
4. van Rhijn BW, van Leenders GJ, Ooms BC, Kirkels WJ, Zlotta AR, Boevé ER, Jöbsis AC, van der Kwast TH: The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading. Eur Urol 2010;57: 1052-1057.
5. May M, Brookman-Amissah S, Roigas J, Hartmann A, Störkel S, Kristiansen G, Gilfrich C, Borchardt R, Hoschke B, Kaufmann O, Gunia S: Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: A multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol 2010;57:850-858.
6. MacLennan GT, Kirkali Z, Cheng L: Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol 2007; 51:889-897.
7. Montironi R, Lopez-Beltran A, Scarpelli M, Mazzucchelli R, Cheng L: 2004 World Health Organization classification of the noninvasive urothelial neoplasms: Inherent problems and clinical reflections. Eur Urol 2009;8:453-457.
8. Heyderman E, Brown BM, Richardson TC: Epithelial markers in prostatic, bladder, and colorectal cancer: An immunoperoxidase study of epithelial membrane antigen, carcinoembryonic antigen, and prostatic acid phosphataise. J Clin Pathol 1984;37:1363-1369.
9. Takashi M, Murase T, Kinjo T, Mitsuya H, Nagura H: Epithelial membrane antigen as an immonohistochemical marker for transitional cell carcinoma of the urinary bladder. Urol Int 1987;42:170-175.
10. Lopez-Beltran A, Croghan GA, Croghan I, Gaeta JF: Cell and tumor markers' immunohistochemistry in transitional cell carcinoma of the bladder. Urol Int 1993;50:61-64.
11. Asamoto M, Fukushima S, Oosumi H, Tatemoto Y, Mori M: Immunohistochemical distribution of epithelial membrane antigen in bladder carcinomas as detected with a monoclonal antibody. Urol Res 1989:17:273-277.
12. Ohtsuki Y, Kuroda N, Umeoka, T, Watanabe R, Ochi K, Okada Y, Lee GH, Furihata M: KL-6 is another useful marker in assessing a micropapillary pattern in carcinomas of the breast and urinary bladder, but not the colon. Med Mol Morphol 2009;42:123-127.
13. Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R: Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: A systematic immunohistochemical analysis of 188 cases. Mod Pathol 2004;17:180-188.
14. Walsh MD, Hohn BG, Thong W, Devine PL, Gardiner RA, Samaratunga ML, McGuckin MA: Mucin expression by transitional cell carcinomas of the bladder. Br J Urol 1994;73:256-262.
15. Nassar H, Pansare V, Zhang H, Che M, Sakr W, Ali-Fehmi R, Grignon D, Sarkar F, Cheng J, Adsay V: Pathogenesis of invasive micropapillary carcinoma: Role of MUC1 glycoprotein. Mod Pathol 2004;17:1045-1050.
16. Jankovic Velickovic L, Katic V, Hattori T, Kushima R, Marjanovic G, Stefanovic V: Differences in the expression of mucins in various forms of cystitis glandularis. Pathol Res Pract 2007;203:653-658.
17. Sangoi AR, Higgins JP, Rouse RV, Schneider AG, McKenney JK: Immunohistochemical comparison of MUC1, CA125 and Her2Neu in invasive micropapillary carcinoma of the urinary tract and typical invasive urothelial carcinoma with retraction artifact. Mod Pathol 2009;22:660-667.
18. Patriarca C, Colombo P, Pio Taronna A, Wesseling J, Franchi G, Guddo F, Naspro R, Macchi RM, Giunta P, Di Pasquale M, Parente M, Arizzi C, Roncalli M, Campo B: Cell discohesion and multifocality of carcinoma in situ of the bladder: New insight from the adhesion molecule profile (e-cadherin, Ep-CAM, and MUC1). Int J Surg Pathol 2009;17:99-106.
19. Lau SK, Weiss LM, Chu PG: Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: An immunohistochemical study. Am J Clin Pathol 2004;122: 61-69.
20. Simms MS, Hughes OD, Limb M, Price MR, Bishop MC: MUC1 mucin as a tumour marker in bladder cancer. BJU Int 1999; 84:350-352.
21. Elbe JN, Sauter G, Epstein JI, Sesterhenn IA (editors): World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, IARC Press, 2004, pp 115-118.
22. Brey EM, Lalani Z, Johnston C, Wong M, McIntire LV, Duke PJ, Patrick CW Jr: Automated selection of DAB-labeled tissue for immunohistochemical quantification. J Histochem Cytochem 2003;51:575-584.
23. Rangan G, Tesch G: Quantification of renal pathology by image analysis. Nephrology 2007;12:553-558.
24. Remmele W, Schicketanz KH: Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer: Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract 1993;189:862-866.
25. Kohlberger PD, Breitenecker F, Kaider A, Lösch A, Gitsch G, Breitenecker G, Kieback DG: Modified true-color computerassisted image analysis versus subjective scoring of estrogen receptor expression in breast cancer: A comparison. Anticancer Res 1999;19:2189-2193.
26. Scholfield DP, Simms MS, Bishop MC: MUC1 mucin in urological malignancy. BJU Int 2003;91:560-566.
27. Garbar C, Mascaux C, Wespes E: Expression of MUC1 and Sialyl-Tn in benign prostatic glands, high-grade prostate intraepithelial neoplasia and malignant prostatic glands: A preliminary study. Anal Quant Cytol Histol 2008;30:71-77.
28. Rahn JJ, Dabbagh L, Pasdar M, Hugh JC: The importance of MUC1 cellular localization in patients with breast carcinoma: An immunohistologic study of 71 patients and review of the literature. Cancer 2001;91:1973-1982.
29. Guo Q, Tang W, Inagaki Y, Midorikawa Y, Kukudo N, Sugawara Y, Nakata M, Konishi T, Nagawa H, Makuuchi M: Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues. World J Gastroenterol 2006;12:54-59.
30. Hughes OD, Bishop MC, Perkins AC, Wastie ML, Denton G, Price MR, Frier M, Denley H, Rutherford R, Schubiger PA: Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595. J Clin Oncol 2000;18:363-370.
31. Taylor-Papadimitriou J, Burchell JM, Plunkett T, Graham R, Correa I, Miles D, Smith M: MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 2002;7:209-221.
32. Abd Elazeez TA, El-Balshy A-L, Khalil MM, El-Tabye MM, Abdul-Halim H: Prognostic significance of P27 (Kip 1) and MUC1 in papillary transitional cell carcinoma of the urinary bladder. Urol Ann 2011;3:8-13.